✦ LIBER ✦

A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies

✍ Scribed by Nemunaitis, John J; Small, Karen A; Kirschmeier, Paul; Zhang, Da; Zhu, Yali; Jou, Ying-Ming; Statkevich, Paul; Yao, Siu-Long; Bannerji, Rajat

Book ID: 121612110
Publisher: BioMed Central
Year: 2013
Tongue: English
Weight: 353 KB
Volume: 11
Category: Article
ISSN: 1479-5876
DOI: 10.1186/1479-5876-11-259

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I evaluation of seliciclib (R-rosc

Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies

✍ Christophe Le Tourneau; Sandrine Faivre; Valérie Laurence; Catherine Delbaldo; K 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 378 KB

405 POSTER A phase I dose-escalation stu

405 POSTER A phase I dose-escalation study of the safety and pharmacokinetics of a XL184, a VEGFR and Met kinase inhibitor, administered orally to subjects with advanced malignancies

✍ R. Kurzrock; L. Camacho; D. Hong; C. Ng; L. Janisch; M.J. Ratain; R. Salgia 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 90 KB

A phase I, first-in-human dose-escalatio

A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumors

✍ Raoul Tibes, Gil Fine, Gavin Choy, Sanjeev Redkar… 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 232 KB

342 POSTER A phase I dose-escalation and

342 POSTER A phase I dose-escalation and pharmacokinetic (PK) study of XL647, a novel spectrum selective kinase inhibitor, administered orally to patients with advanced solid malignancies (ASM)

✍ B.I. Sikic; H.A. Wakelee; A.A. Adjei; J. Halsey; J.L. Lensing; J.D. Dugay; L.J. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 68 KB

Phase I dose escalation study of MK-0457

Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors

✍ Anne M. Traynor; Maureen Hewitt; Glenn Liu; Keith T. Flaherty; Jason Clark; Stev 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 252 KB

390 POSTER A Phase I dose-escalation stu

390 POSTER A Phase I dose-escalation study of XL228, a potent IGF1R / Src inhibitor, in patients with advanced malignancies

✍ C. Britten; D.C. Smith; L.A. Bui; D.O. Clary; H.I. Hurwitz 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 57 KB